Premium
Quantitative export of FGF‐2 occurs through an alternative, energy‐dependent, non‐ER/Golgi pathway
Author(s) -
Florkiewicz Robert Z.,
Majack Richard A.,
Buechler Robbie D.,
Florkiewicz Elin
Publication year - 1995
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.1041620311
Subject(s) - brefeldin a , microbiology and biotechnology , golgi apparatus , signal peptide , transfection , fibroblast growth factor , biology , biochemistry , chemistry , endoplasmic reticulum , peptide sequence , gene , receptor
Abstract Although basic fibroblast growth factor (bFGF/FGF‐2) is found outside cells, it lacks a conventional signal peptide sequence; the mechanism underlying its export from cells is therefore unknown. Using a transient COS‐1 cell expression system, we have identified a novel membrane‐associated transport pathway that mediates export of FGF‐2. This export pathway is specific for the 18‐kD isoform of FGF‐2, is resistant to the anti‐Golgi effects of Brefeldin A, and is energy‐dependent. In FGF‐2‐transfected COS‐1 cells, this ER/Golgi‐independent pathway appears to be constitutively active and functions to quantitatively export metabolically‐labeled 18‐kD FGF‐2. Co‐transfection and co‐immunoprecipitation experiments, using a vector encoding the cytoplasmic protein neomycin phosphotransferase, further demonstrated the selectivity of this export pathway for FGF‐2. When neomycin phosphotransferase was appended to the COOH‐terminus of 18‐kD FGF‐2, the chimera was exported. However, the transmembrane anchor sequence of the integral membrane glycoprotein (G protein) of vesicular stomatitis virus (VSV) blocked export. The chimeric protein localized to the plasma membrane with its FGF‐2 domain extracellular and remained cell‐associated following alkaline carbonate extraction. Taken together, the data suggest that FGF‐2 is “exported” from cells via a unique cellular pathway, which is clearly distinct from classical signal peptide‐mediated secretion. This model system provides a basis for the development and testing of therapeutic agents which may block FGF‐2 export. Such an intervention may be of considerable use for the treatment of angiogenesis‐dependent diseases involving FGF‐2. © 1995 Wiley‐Liss, Inc.